{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:14:58Z","timestamp":1790036098560,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.japh.2022.12.019","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T20:17:44Z","timestamp":1671481064000},"page":"817-824.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2627-300X","authenticated-orcid":false,"given":"Olajide A.","family":"Adekunle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Seoane-Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4532-7640","authenticated-orcid":false,"given":"Lawrence M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.japh.2022.12.019_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/2230-8210.85575","article-title":"Gonadotropin-releasing hormone agonists: expanding vistas","volume":"15","author":"Magon","year":"2011","journal-title":"Indian J Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.japh.2022.12.019_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"European association of Urology. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.japh.2022.12.019_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000209352","article-title":"Impact of surgical and medical castration on serum testosterone level in prostate cancer patients","volume":"82","author":"Novara","year":"2009","journal-title":"Urologia Internationalis"},{"issue":"4","key":"10.1016\/j.japh.2022.12.019_bib6","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"59","author":"Mottet","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.japh.2022.12.019_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin-releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.japh.2022.12.019_bib8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.eururo.2013.12.063","article-title":"Disease control outcomes from analysis of pooled individual patient data from five comparative randomized clinical trials of degarelix versus luteinizing hormone-releasing hormone agonists","volume":"66","author":"Klotz","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.japh.2022.12.019_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1464-410X.2009.08981.x","article-title":"Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study","volume":"106","author":"Schr\u00f6der","year":"2009","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.japh.2022.12.019_bib10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.eururo.2009.11.029","article-title":"Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80mg versus leuprolide in prostate cancer patients segmented by baseline characteristics","volume":"57","author":"Tombal","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.japh.2022.12.019_bib12","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.japh.2022.12.019_bib14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1046\/j.1464-410X.2003.04308.x","article-title":"For South African Triptorelin Study Group. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer","volume":"92","author":"Heyns","year":"2003","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.japh.2022.12.019_bib15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.clinthera.2010.04.013","article-title":"Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study","volume":"32","author":"Marberger","year":"2010","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.japh.2022.12.019_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2005.09.009","article-title":"Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer","volume":"49","author":"Yri","year":"2006","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.japh.2022.12.019_bib17","first-page":"533","article-title":"A\u00a012-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer","volume":"175","author":"Crawford","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.japh.2022.12.019_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/pcan.2011.50","article-title":"Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer","volume":"15","author":"Spitz","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.japh.2022.12.019_bib27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/erp.13.13","article-title":"Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer","volume":"13","author":"Hatoum","year":"2013","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"issue":"11","key":"10.1016\/j.japh.2022.12.019_bib19","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/cer-2018-0133","article-title":"Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China","volume":"8","author":"Liu","year":"2019","journal-title":"J\u00a0Comp Eff Res"},{"issue":"2","key":"10.1016\/j.japh.2022.12.019_bib26","doi-asserted-by":"crossref","DOI":"10.31744\/einstein_journal\/2019GS4414","article-title":"Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer","volume":"17","author":"Aguiar","year":"2019","journal-title":"Einstein (S\u00e3o Paulo)"},{"key":"10.1016\/j.japh.2022.12.019_bib32","unstructured":"Micromedex red Book \u2013 Truven health Analytics. Available at: www.redbook.com\/redbook\/index.html. Accessed March 17, 2021."},{"issue":"8","key":"10.1016\/j.japh.2022.12.019_bib20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1464-410X.2011.10434.x","article-title":"Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer","volume":"109","author":"Lu","year":"2011","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.japh.2022.12.019_bib21","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0149-2918(02)80087-X","article-title":"A\u00a0six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer","volume":"24","author":"Perez-Marreno","year":"2002","journal-title":"Clin Ther"},{"issue":"9","key":"10.1016\/j.japh.2022.12.019_bib22","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1464-410X.2007.07374.x","article-title":"Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer","volume":"101","author":"Fujii","year":"2008","journal-title":"BJU Int"},{"issue":"3 Pt 1","key":"10.1016\/j.japh.2022.12.019_bib23","first-page":"726","article-title":"Failure to achieve castrate levels of testosterone during luteinizing hormone-releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm","volume":"164","author":"Oefelein","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.japh.2022.12.019_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14656566.2016.1258058","article-title":"Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer","volume":"18","author":"Hoda","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.japh.2022.12.019_bib25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"STAMPEDE investigators. Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122004150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122004150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:52:01Z","timestamp":1761544321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319122004150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1544319122004150"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2022.12.019","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2022.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}